Neuroblastoma screening

Revision as of 16:22, 14 February 2019 by Zahir Ali Shaikh (talk | contribs)
Jump to navigation Jump to search

Neuroblastoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Neuroblastoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Neuroblastoma screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Neuroblastoma screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Neuroblastoma screening

CDC on Neuroblastoma screening

Neuroblastoma screening in the news

Blogs on Neuroblastoma screening

Directions to Hospitals Treating Neuroblastoma

Risk calculators and risk factors for Neuroblastoma screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Zahir Ali Shaikh, MD[2]Haytham Allaham, M.D. [3]

Overview

There is insufficient evidence to recommend the routine screening for neuroblastoma as it has no mortality benefits.

Screening

  • There is insufficient evidence to recommend the routine screening for neuroblastoma by measuring the vanillylmandelic acid and homovanillic acid at 6 months or 1 year or age, as it does not have the mortality benefits.[1][2][3][4]

References

  1. Recommendations. US Preventive Services Task Force(2015) http://www.uspreventiveservicestaskforce.org/BrowseRec/Search?s=neuroblastoma Accessed on October, 5 2015
  2. William G. Woods, Ru-Nie Gao, Jonathan J. Shuster, Leslie L. Robison, Mark Bernstein, Sheila Weitzman, Greta Bunin, Isra Levy, Josee Brossard, Geoffrey Dougherty, Mendel Tuchman & Bernard Lemieux (2002). "Screening of infants and mortality due to neuroblastoma". The New England journal of medicine. 346 (14): 1041–1046. doi:10.1056/NEJMoa012387. PMID 11932470. Unknown parameter |month= ignored (help)
  3. Freimut H. Schilling, Claudia Spix, Frank Berthold, Rudolf Erttmann, Natalja Fehse, Barbara Hero, Gisela Klein, Johannes Sander, Kerstin Schwarz, Joern Treuner, Ulrich Zorn & Joerg Michaelis (2002). "Neuroblastoma screening at one year of age". The New England journal of medicine. 346 (14): 1047–1053. doi:10.1056/NEJMoa012277. PMID 11932471. Unknown parameter |month= ignored (help)
  4. "Neuroblastoma Screening (PDQ(R)): Health Professional Version". 2002. PMID 26389460.


Template:WikiDoc Sources